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ABSTRACT
Combined Pituitary Hormone Deficiency (CPHD) is a prevalent disease in Neuroen-
docrinology services. The genetic form of CPHD may originate from mutations in pituitary
transcription factor (PTF) genes and the pituitary image in these cases may give a clue of
what PTF is most probably mutated: defects in LHX4 are usually associated with ectopic
posterior pituitary (EPP); defects in LHX3, PIT1, and PROP1, with normally placed posteri-
or pituitary (NPPP); HESX1 mutations are associated with both. Objective: To identify
mutations in PTF genes in patients with idiopathic hypopituitarism followed in our ser-
vice, based on the presence or absence of EPP on sellar MRI. Methods: Forty patients
with idiopathic hypopituitarism (36 families, 9 consanguineous), followed in the Neu-
roendocrinology Outpatient Clinic of UNIFESP, Brazil, were submitted to sequencing
analyses of PTF genes as follows: LHX3, HESX1, PIT1, and PROP1 were sequenced in
patients with NPPP (26/40) and HESX1 and LHX4 in patients with EPP (14/40). Results:
We identified only PROP1 mutations in 9 out of 26 patients with CPHD and NPPP (35%).
Since eight of them came from 4 consanguineous families, the prevalence of PROP1
mutations was higher when only consanguineous families were considered (44%, 4/9). At
the end of the study, we decided to sequence PROP1 in patients with EPP, just to confirm
that they were not candidates for PROP1 mutations. No patients with EPP had PROP1 or
other PTF mutations. Conclusions: Patients with idiopathic CPHD and NPPP, born from
consanguineous parents, are the strong candidates for PROP1 mutations. Other develop-
mental gene(s) may be involved in the genesis of idiopathic hypopituitarism associated
with EPP. (Arq Bras Endocrinol Metab 2007;51/7:1097-1103)
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RESUMO
Análise Molecular de PROP1, PIT1, HESX1, LHX3 e LHX4 Mostra Alta
Freqüência de Mutações no PROP1 em Pacientes com Formas Familiares de
Deficiência Combinada de Hormônios Hipofisários.
Deficiência Combinada de Hormônios Hipofisários (DCHH) é uma doença prevalente em
todos os serviços de Neuroendocrinologia. A DCHH de origem genética pode resultar de
mutações nos genes de fatores de transcrição hipofisários (FTH), e a ressonância
magnética (RM) de sela desses pacientes pode indicar qual FTH tem maior probabilidade
de estar mutado: mutações no LHX4 estão geralmente associadas a neuro-hipófise
ectópica (NHE); mutações no LHX3, PIT1 e PROP1, a neuro-hipófise tópica (NHT);
mutações no HESX1 podem estar associadas a NHE e NHT. Objetivo: Identificar
mutações nos FTH em pacientes acompanhados em nosso serviço, portadores de
hipopituitarismo idiopático, selecionando os genes a serem estudados de acordo com a
presença ou ausência de NHE à RM sela. Métodos: Os genes dos FTH foram
seqüenciados em 40 pacientes com hipopituitarismo idiopático (36 famílias, 9
consangüíneas), acompanhados na unidade de Neuroendocrinologia da UNIFESP, SP,
Brasil: LHX3, HESX1, PIT1 e PROP1 foram seqüenciados nos pacientes com NHT (26/40)
e HESX1 e LHX4, nos pacientes com NHE (14/40). Resultados: Somente mutações
PROP1 foram identificadas em 9 de 26 pacientes (35%) com NHT, 8 deles provenientes de
4 famílias consangüíneas (4/9, 44%). Uma vez que mutações no PROP1 foram tão
freqüentes, decidimos, ao final do estudo, seqüenciá-lo também nos pacientes com NHE.
Nenhum paciente com NHE apresentou mutações no PROP1 ou em outro FTH.
Conclusão: Mutações no gene PROP1 foram encontradas em 22,5% (9/40) de todos os
pacientes, em 35% (9/26) dos pacientes com NHT e em 44% (4/9) se considerarmos
somente as famílias consangüíneas. Portanto, pacientes com DCHH idiopática e NHT,
provenientes de famílias de pais consangüíneos, são os melhores candidatos a mutações
PROP1. (Arq Bras Endocrinol Metab 2007;51/7:1097-1103)
Descritores: Fator de transcrição hipofisário; PROP1; Hipopituitarismo; Deficiência
combinada de hormônios hipofisários
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COMBINED PITUITARY HORMONE Deficiency(CPHD) includes a heterogeneous group of disor-
ders characterized by impaired production of growth
hormone (GH) and one or more of the other anterior
pituitary hormones, and it is a prevalent disease in all
Neuroendocrinology services. Clinically, CPHD is
characterized by a combination of the following find-
ings: short stature, hypothyroidism, impaired sexual
development and hypocortisolism. CPHD may result
from acquired lesions in the hypothalamic-pituitary
region (tumor, trauma, surgery, irradiation), from
genetically defined conditions, or may be idiopathic.
CPHD from genetic cause has an incidence of approx-
imately 1:8,000 births and is usually sporadic, but near-
ly 5–30% of cases are familial (1-3).
During pituitary embryogenesis, homeobox
genes (HESX1, PITX1 and 2, LHX3, LHX4, SIX6,
PROP1, PIT1, TPIT, and SOX3) become activated in
the region of the future anterior pituitary gland, fol-
lowing a specific temporal and spatial pattern of acti-
vation. They encode pituitary transcription factors
(PTF), which are nuclear proteins that bind to regula-
tory DNA sequences of target genes, activating or
inhibiting their transcription. The PTF are involved in
the development of the anterior pituitary gland, from
the thickening and invagination of the roof of the
primitive oral cavity, to the terminal differentiation of
the five different pituitary cell types (somatotrophs,
lactotrophs, thyrotrophs, gonadotrophs, and corti-
cothophs) (4). PTF may be pituitary-specific (PIT1,
PROP1, TPIT) or pituitary non-specific (HESX1,
PITX1 and 2, LHX3, LHX4, SIX6, SOX3). The latter
are also expressed in other regions such as the anterior
central nervous system (HESX1, SOX3), the eyes
(PITX2, SIX6), the teeth, the heart (PITX2), the cer-
vical spine (LHX3), the cerebellum (LHX4), and the
spinal cord (SOX3) (5,6).
Mutations in HESX1, LHX3, LHX4, PROP1,
PIT1 genes lead to the genetic form of CPHD. Clini-
cally, the patients may present two or more deficien-
cies of the anterior pituitary hormones. At times, the
hypopituitarism may present as an isolated anterior
pituitary hormone deficiency (usually GH deficiency),
which gradually evolves to CPHD (5,7,8). HESX1
mutations cause either isolated GH deficiency or
CPHD, associated or not with other anomalies such as
septo-optic dysplasia and agenesis of the corpus callo-
sum (5,9,10); LHX3 mutations lead to GH, TSH,
PRL, and gonadotrophin deficiencies, associated with
short cervical spine and limited neck rotation (11-14);
LHX4 mutations cause GH, TSH, and ACTH defi-
ciencies and cerebellar abnormalities (15). Defects in
PIT1 gene cause GH, TSH, and PRL deficiencies, and
in PROP1 cause deficiencies in pituitary hormones
produced by PIT1 dependent cell lineages (soma-
totrophs, thyrotrophs, lactotrophs), as well as evolving
gonadotrophin and corticotrophin deficiencies
(3,8,16-19).
The sellar magnetic resonance image (MRI)
findings in patients with PTF mutations are variable
and may give a clue of what PTF is most probably
mutated: LHX4 mutations are usually associated with
an EPP, whereas PIT1, PROP1, and LHX3 mutations
are associated with NPPP. HESX1 mutations may be
associated with EPP or NPPP (5,20-22). With regard
to the image of the anterior pituitary, the majority of
the patients with PTF mutations have a hypoplastic or
normal anterior pituitary gland, but an enlarged pitu-
itary mass resembling hyperplasia of the adeno-
hypophysis may be detected less frequently in some
patients with PROP1 mutations.
In this study, we searched for mutations in
HESX1, LHX3, LHX4, PIT1, and PROP1 genes in a
cohort of patients with idiopathic hypopituitarism who
are followed in our neuroendocrine service. The objec-
tive of this search was to identify the prevalence of PTF
gene mutations in our patients and to correlate the
mutations identified with the different CPHD pheno-
types, improving our understanding about some
genetically identified cases of CPHD.
PATIENTS AND METHODS
Patients
Patients with idiopathic hypopituitarism who are followed in
the Neuroendocrinology Outpatient Clinic of the Universi-
dade Federal de São Paulo (UNIFESP), in São Paulo, Brazil,
were recruited into the study. After obtaining approval for
the study protocol by the Institutional Ethics Committee,
informed written consent was obtained from the patients
who agreed to participate of the study.
Forty patients (30 males, 10 females) with a mean
age at the diagnosis of hypopituitarism of 11.4 years (range
0.5–37 yr) participated in the study. Thirteen patients were
born from consanguineous marriages (9 consanguineous
families) and all patients had GH deficiency. The different
pituitary hormonal deficiency profiles, the imaging findings
and the characteristics of the patients are listed in tables 1
and 2. The patients were divided in two groups: Group 1–
idiopathic hypopituitarism and ectopic posterior pituitary
(EPP): 14 patients (10 males : 4 females). All patients from
this group had initially HESX1 and LHX4 genes sequenced.
However, since PROP1 mutations were so common, we
decided to sequence PROP1 in these patients later on in the
study. Group 2– idiopathic hypopituitarism and normally
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Table 1. Clinical, hormonal and radiological features of the 14 patients with ectopic posterior pituitary.
Patients Sex Age at Dx Z Stature Current CONS Pituitary Pituitary Pituitary Pituitary Pituitary Sellar MRI: GH peak Mutation
of Hipopit. at Dx of Age Hormone Hormone Hormone Hormone Hormone EPP after ITT
(years) Hipopit (years) Deficiencies Deficiencies Deficiencies Deficiencies Deficiencies associated (ng/ml)
with:
GH TSH PRL GNT ACTH
1 F 7.9 -4.1 27 N + + + + + small sella 0.57 —
2 F 0.5 -2.5 8.1 N + + + + SP agenesis 0.8 —
3 F 2 -2.3 8 N + + + + stalk agenesis 1.7 —
4 M 8.3 -3.8 9.9 N + + + + 0.4 —
5 M 10.3 -5.2 24 + + + + APH 1.7 —
6 M 2.5 -2.8 13.9 N + + + thin stalk 0.8 —
7 M 7.1 -1.9 8.1 N + + + APH 0.05 —
8 M 9.9 -4.9 21 + + + APH —
9 F 18 -3.3 24 N + + 0.8 —
10 M 8.7 -4.5 17 N + + 1.75 —
11 M 11.5 -4.7 11.8 N + + 0.2 —
12 M 4.5 -3.9 8.9 N + small sella 1.0 —
13 M 14 -4.9 18.2 N + 0.5 —
14 M 11.1 -2.5 12.3 N + 2.7 —
Cons = consanguinity, N = No, EPP = Ectopic posterior pituitary, SP = septum pellucidum, APH = anterior pituitary hypoplasia.
Table 2. Clinical, hormonal, and radiological features of the 26 patients with normally placed posterior pituitary.
Patients Sex Age at Dx Z Stature Current CONS Pituitary Pituitary Pituitary Pituitary Pituitary Sellar GH peak Mutation
of Hipopit. at Dx of Age Hormone Hormone Hormone Hormone Hormone MRI after ITT
(years) Hipopit (years) Deficiencies Deficiencies Deficiencies Deficiencies Deficiencies (ng/ml)
GH TSH PRL GNT ACTH
15* F 11 -6.0 24 Y + + + + + Normal pit. 1.2 PROP1
(family I) 301302delAG
16* F 10 -4.9 22 Y + + + + + Norma pit. 0.2 PROP1
(family I) 301302delAG
17 M 5 -4.2 8 Y + + + + Nomal pit. 0.9 PROP1
(family II) 301302delAG)
18 M 8 -4.9 11 Y + + + + Normal pit. 0.4 PROP1
(family II) (301302delAG
19* F 10 -6.0 24 N + + + + + APH < 0.5 PROP1
(family III) 301302delAG
20* F 15 -2.6 26 Y + + + + APH 0.2 PROP1
(family IV) R99Q
21* M 17 -4.0 25 Y + + + + APH 0.45 PROP1
(family IV) R99Q
22* M 29 -1.0 41 Y + + + + + APH 1.4 PROP1
(family V) R120C
23* M 37 -3.4 39 Y + + + + + APH IGFI: PROP1
(family V) 21 ng/mL R120C
24 M 8.2 -3.9 25 N + + + + + APH 1.1 —
25 M 12.9 -5.8 29 N + + + + + APH 0.27 —
26 F 19 n.a. 22 Y + + + + APH 0.05 —
27 M 14 -5.1 31 N + + + + APH 3.1 —
28 M 12.5 -4.4 23 Y + + + + APH n.a. —
29 M 12.8 -4.3 26 N + + + APH 2.4 —
30 M 8.6 -4.1 20 N + + + APH n.a. —
31 M 17 -8.38 22 Y + + + APH 0.7 —
32 M 4 -2.9 7 Y + + C.C. 3.2 —
Agenesis
33 M 3.8 -4.4 21 N + + Pit Stalk 3.0 —
Agenesis
34 M 15 -3.9 20 N + + + APH; CIL 1.7 —
35 F 6.1 -3.2 8 Y + + APH 0.6 —
36 M 13 -4.7 25 N + + + APH 2.9 —
37 M 9 -5.2 12 N + APH 0.8 PROP1
polymorphism 
P58P
38 M 11 -3.2 13 N + APH 0.2 —
39 M 6.8 -3.9 11 N + APH 0.1 —
40 M 7.5 -3.7 12 N + Normal 0.6 —
pit.
* families reported before, Cons = consanguinity, Y = Yes, N = No, APH = anterior pituitary hypoplasia, C.C. = Corpus Calosum,
CIL = cyst intermidiate lobe, n.a. = not available.
placed posterior pituitary (NPPP): 26 patients (20 males : 6
females). All the patients of this group had HESX1, LHX3,
PROP1, and PIT1 genes sequenced, but only the patients
with GH, TSH, and PRL or GH and TSH deficiencies had
the PIT1 gene sequenced (5 patients).
Clinical, hormonal and radiological 
evaluation
Clinical data from some of the patients were obtained retro-
spectively from the patients’ records and included history of
consanguinity, family history, auxological data, parental
heights and anterior pituitary hormone evaluation. Other
patients were included in the study as soon as the diagnosis
of hypopituitarism was made. To assess anterior pituitary
function, hormone levels were measured at baseline (TSH,
free T4, PRL, LH, FSH, IGF-I, cortisol, estradiol/testos-
terone) and a combined pituitary stimulation test was per-
formed when necessary. For the combined test, glucose,
GH, cortisol, TSH, PRL, LH, and FSH were measured
before and at 15, 30, 45 and 60 min after iv administration
of 0.1 U/kg insulin, 200 µg TRH, and 100 µg GnRH.
The following were the diagnostic methods used for
hormonal measurements: i) Free T4, TSH, PRL, GH, LH,
and FSH: flurometric assay (Delfia, Wallac Oy, Turku, Fin-
land); ii) cortisol: RIA (Diagnostic Products, Los Angeles,
CA, USA); iii) IGF-I: Immunoflorimetric assay after ethanol
extraction using specific monoclonal antibodies (DSL kit).
The criteria used for the diagnosis of GH deficiency
were auxological, hormonal, and radiological: poor growth
velocity (more than 1 SD below the mean for age), IGF-I
low for age, abnormal GH peak response (< 3 ng/ml) to
hypoglycemia on Insulin Tolerance Test (ITT) and anatom-
ic pituitary abnormalities on MRI. Some patients with
abnormal sellar MRIs had only one GH stimulation test per-
formed (ITT). All patients with normal sellar MRIs were
submitted to a second GH stimulation test with clonidine.
Not all patients had IGF-I measured.
Radiological studies of the sella turcica were per-
formed in a Philips Gyroscan ACS-NT 1,5 tesla. The coro-
nal images were obtained using 2-mm slices. The maximal
height of the pituitary was measured perpendicularly to the
sella turcica. The classification of the size of the anterior
pituitary (normal, small or increased) was made accordingly
to the normal controls from the studies of Tsunoda and
Argyroupoulous (9,30).
Genomic analysis
DNA was extracted from peripheral lymphocytes of the
patients using a Quiagen Midi Kit (Quiagen), following the
manufacturer’s protocol.
All coding exons of HESX1, LHX3, LHX4, PIT1,
PROP1 genes were amplified by Polymerase Chain Reaction
(PCR). One hundred nanograms of human genomic DNA
were used as template in a 100 uL PCR mixture containing
20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2,
0.2 mM deoxy-NTPs, 2.5 U Taq polymerase (PCR Reagent
System, Life-Technologies) and 0.1 nM of upstream and
downstream specific primers. The sequence of the PCR
primers and the PCR thermal cycling program have been
described elsewhere (9,14,15,19,31). PCR products were
analyzed in 1.8% agarose gel and purified using a PCR Prod-
uct Purification Kit (Life Technologies, USA). Direct
sequencing of the PCR products was carried out in both
directions, using the ABI Prism Big Dye terminator cycle
sequencing ready reaction version 3.0 (Applied Biosystems)
in an ABI Prism 3100 DNA Sequencer (Perkin Elmer Cor-
poration).
RESULTS
Genomic sequencing of the homeobox
genes
Three different PROP1 homozygous gene mutations
[301-302delAG (exon 2), 358C>T (exon 3), and
296G>A (exon2)], were found in 9 patients, all of
them with normally placed posterior pituitary (table
2). They were four pairs of siblings from 4 families of
consanguineous parents, and one patient from a non-
consanguineous family (table 2). The 301-302delAG
mutation leads to a frame shift and a truncated PROP1
protein with null function. The 358C>T missense
mutation predicts an amino acid change at codon 120
replacing a much conserved arginine by a cysteine
(R120C) in the third helix of the DNA-binding
domain of the PROP1, and the mutant protein has an
eight-fold reduction in DNA binding affinity and
impaired trans-activation activity (17). The mutation
296G>A predicts an amino acid change at codon 99
replacing a highly conserved arginine by a glutamine
(R99Q) in the second helix of the paired DNA-bind-
ing homeodomain of PROP1. The mutant protein
presents a weak binding to its target DNA sequence
but still preserves some functional activity (32).
We also identified in one patient a PROP1 het-
erozygous polymorphism CCG/CCA, in exon 2 of
PROP1 (nucleotide position 1965). This polymor-
phism does not change the amino acid in the PROP1
protein (P58P) and has been found in normal popula-
tions (OMIM SNP rs2233784).
No mutations were found in HESX1, LHX3,
LHX4 or PIT1 genes in all the patients tested. No
mutations were found in patients with EPP.
DISCUSSION
In the present study, we performed mutational analy-
sis of the HESX1, LHX3, LHX4, PROP1, and PIT1
genes in a cohort of 40 patients with idiopathic
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hypopituitarism followed in one large neuroen-
docrinology service of the southeast region of Brazil,
the Neuroendocrinology Clinic / Medicine Depart-
ment of Escola Paulista de Medicina, Universidade
Federal de São Paulo. Since LHX4 and HESX1 are
more likely to be associated with EPP, and LHX3,
PIT1, PROP1, and HESX1 with NPPP (5), we divid-
ed the patients in two groups, according to the pres-
ence or not of EPP on sellar MRI, and searched the
candidate genes in each group.
We identified 3 different PROP1 mutations
(301-302delAG, R99Q, and R120C) in 9 patients, all
of them with CPHD and NPPP. The patients with EPP
showed no mutations in the genes studied (HESX1,
LHX4, and PROP1) and this is compatible with the rar-
ity of PTF mutations found in patients with EPP
(10,15,20,33,34). Perhaps other developmental genes
yet to be identified may be involved in the etiology of
EPP, or another pathogenic mechanism could be
responsible for this abnormality (35,36).
The 9 patients who carry PROP1 mutations are
four pairs of siblings belonging to four independent
consanguineous families, and one patient born from
non-consanguineous parents. They correspond to
22.5% (9/40) of all patients in this cohort. If we con-
sider only the consanguineous families, 44% of them
(4/9) had members with PROP1 mutations. The high
prevalence of PROP1 mutations in our patients from
consanguineous families reinforces previous studies
that reported PROP1 mutations in 36 to 50% of all
familial cases of CPHD (3,19,33,37,38). On the other
hand, the absence of molecular abnormalities in the
other PTF genes studied reinforces the scarcity of these
mutations and points to the possible involvement of
other developmental genes in the pathogenesis of the
remaining cases of idiopathic hypopituitarism (1).
The most prevalent PROP1 mutation in our
cohort was the 301-302delAG in exon 2, found in 5
patients from 3 families. Two of them have been
reported before (28,39). This mutation is so common
that it is considered by several authors as a mutational
hotspot (19,25). All five patients with the 301-302del
AG presented severe short stature and signs of GH and
TSH deficiencies before the age of 10 years. All the
adult patients bearing this mutation also presented
gonadotrophin deficiency. Because this mutation cod-
ifies a truncated protein with null function, it leads to
a severe CPHD phenotype, affecting all the anterior
pituitary hormones. The ACTH deficiency usually
occurs in the third decade of life (17-19,23,25,39). In
our cohort of patients, the older brother from family
II presented a slightly compromised cortisol response
to hypoglycemia (15.4 µg/dl) at the age of 11 years,
and the patients from families I and III presented
ACTH deficiency at the ages of 16 and 17 years (table
3). Hypocortisolaemia occurring during the second
decade of life is an uncommon finding but has been
described before (37,40).
The other two mutations found (R99Q and the
R120C) are rarer. The PROP1 358C>T (R120C) mis-
sense mutation identified in family V has never been
described in Brazilian families, and only a few families
of European, Mexican-American, and Jewish-Moroc-
can origins have been reported before (7,17,41-43).
The two brothers, born from a consanguineous mar-
riage, developed progressive CPHD but were only
diagnosed in adulthood (at 29 and 37 years of age).
The central hypothyroidism was mild in both cases,
GH deficiency was very mild in one case, hypogo-
nadism was equally severe in both cases, and ACTH
deficiency appeared at different ages (table 3). This
illustrates the heterogeneity of this mutation.
The other mutation present in this cohort of
patients, R99Q, in family IV, is also responsible for a
progressive CPHD phenotype and was reported by
our group three years ago. In this family, the younger
brother had been diagnosed in childhood with familial
short stature and constitutional delay of growth, and
only in the second decade of life the diagnosis of GH
deficiency associated with other pituitary deficiencies
was established. The same happened with his older sis-
ter who looked for medical attention only at the age of
15 years for lack of puberty, while her stature was
compatible with her target height and she had no
symptoms of other pituitary hormone deficiencies
(table 3). The phenotype of these siblings is also com-
patible with a mild PROP1 deficiency (32).
One last remark is the predominance of male
patients with CPHD in our cohort (3:1, M:F). Muta-
tions in SOX3, another pituitary transcription factor
gene located at Xq26, have recently been described in
males with congenital X-linked hypopituitarism. These
patients may present mental retardation and/or
anatomical abnormalities in the corpus callosum and
pituitary (44,45). The molecular study of this gene in
our male patients is planned for the near future.
In summary, our cohort of patients shows that
PTF gene mutations such as HESX1, LHX3, LHX4,
and PIT1 are rare in patients with idiopathic hypopi-
tuitarism. On the other hand, PROP1 mutations are
common among patients with CPHD and normally
placed posterior pituitary that are born from consan-
guineous parents. Therefore, patients with these fea-
tures are the strong candidates for PROP1 mutations.
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Table 3. Hormonal profile of the patients with PROP1 mutations.
Patient / Sex Age at Height FT4 (ng/dl) / PRL IGF-I Peak GH Cortisol LH / FSH Testo
Mutation diagnosis (cm) TSH (U/L) (ng/ml) ng/ml (ng/ml) (ug/dl) (U/L) ng/dl
(years) after ITT Basal and after GnRH
Peak (ITT)
15 F 11 103.5 0.3/1.8 3.9 — 1.2 P > 18 (11 yr) 0.2/0.2 —
(family I) (-6.0 SD) B: 4.5 (16 yr)
301-302delAG
16 F 10 103 0.6/2.6 4.5 — 0.2 P > 18 (10 yr) 0.1/0.3 —
(family I) (-4.9 SD) B: 2.2 (16 yr)
301-302delAG
17 M 5 90 0.6/2.0 11.2 < 6 0.9 P: 18.3 (8 yrs) n.d. n.d.
(family II) (-4.2 SD)
301-302delAG
18 M 8 101 0.7/1.1 9.4 < 6 0.4 P: 15.4 (11 yrs) B: < 0.1/0.3 n.d.
(family II) (-4.9 SD)
301-302delAG
19 F 10 99 TT4*: 3.8/2.8 1.2 41.3 < 0.5 B: 2.1 (17 yr) < 1.5/< 1.5 —
(family III) (-6.0 SD)
301-302delAG
20 F 15 144 0.7/1.5 6.9 112 0.2 B: 10 (10 yr) 1.0/5.8 —
(family IV) (-2.6 SD)
R99Q
21 M 17 145.5 0.7/1.0 4.9 88 0.45 P: 18.1 (17 yr) 4.8/2.0 < 30
(family IV) (-4.0)
R99Q
22 M 29 170 0.6/4.7 < 3 — 1.4 P: < 0.9 (29 yr) 8/1 22
(family V) (-1.0 SD)
R120C
23 M 37 154 0.4/3.7 < 3 21 — B: 7.7 (42 yr) B: < 2/< 1 8
(family V) (-3.4 SD) B: 2.0 (45 yr)
R120C
Normal values 0.8–2.7 3–15 ** > 3 B: 5–25 LHB: < 14 Pre-pubertal:
P: > 18 LHP: > 4–6x < 50
adult:
300–950
* TT4 = totalT4 ug/dl (normal values: 4–11 ug/dl), n.d. = not done, B = Basal.
** IGFI normal values: < 6 yr = 20–200 ng/ml, 6–12 yr: 88–450 ng/ml, 13–16 yr: 200–900 ng/ml, 17–24 yr: 180–780 ng/ml, 25–39 yr: 114–400 ng/ml.
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